View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Deals Analysis
May 26, 2022

Asia-Pacific’s medical devices industry saw a drop of 25.58% in deal activity during April 2022

By Carmen

Asia-Pacific’s medical devices industry saw a drop of 25.58% in deal activity during April 2022, when compared with the last 12-month average, led by Winner Medical Group’s $114.35m acquisition of 55% stake in Zhejiang Longtai Medical Technology, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

A total of 32 medical devices industry deals worth $382m were announced for the region in April 2022, against the 12-month average of 43 deals.

Of all the deal types, venture financing saw most activity in April 2022 with 28 transactions, representing an 87.5% share for the region.

In second place was M&A with four deals capturing a 12.5% share of the overall deal activity for the month.

In terms of value of deals, M&A was the leading category in Asia-Pacific’s medical devices industry with $193.19m, followed by venture financing deals totalled $188.77m.

Asia-Pacific medical devices industry deals in April 2022: Top deals

The top five medical devices deals accounted for 76.02% of the overall value during April 2022.

The combined value of the top five medical devices deals stood at $290.35m, against the overall value of $382m recorded for the month.

The top five medical devices industry deals of April 2022 tracked by GlobalData were:

1) Winner Medical Group $114.35m acquisition deal for 55% stake in Zhejiang Longtai Medical Technology

2) The $74.59m acquisition of ResApp Health by Pfizer Australia Holdings

3) Globis Capital Partners &,Incubate Fund,SoftBank Vision Fund 2 and World Innovation Lab (WiL fund) $70m venture financing deal with AI Medical Service

4) The $15.71m venture financing of Shanghai Yipu Biotechnology by Industrial Capital

5) Boyuan Capital,Guotai Junan Innovation Investment and Yinshengtai Capital $15.7m venture financing deal with Shanghai Ruijing Biotechnology

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network